Viamet's Valley Fever candidate granted QIDP status by FDA

19 September 2016
2019_biotech_test_vial_discovery_big

US biotech Viamet Pharmaceuticals has been granted qualified infectious disease product (QIDP) designation by the US Food and Drug Administration (FDA) for VT-1598, a novel candidate for the oral treatment of coccidioidomycosis, or Valley fever.

QIDP designation provides significant incentives for the development of innovative antimicrobial agents like VT-1598, including the potential for priority review by the FDA, eligibility for fast track status, and a five-year extension of marketing exclusivity.

The FDA granted orphan drug designation to VT-1598 in May for the treatment of Valley fever, which is a systemic fungal infection in the south west of the USA, where the spores of the fungal pathogen Coccidioides live in the soil.  There are an estimated 150,000 cases annually and a major need exists for new treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology